* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Download Product Monograph
Prescription costs wikipedia , lookup
Neuropharmacology wikipedia , lookup
Clinical trial wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Discovery and development of direct thrombin inhibitors wikipedia , lookup
Theralizumab wikipedia , lookup
ï· Lesions or conditions at increased risk of clinically significant bleeding, e.g., recent cerebral infarction (hemorrhagic or ischemic), active peptic ulcer disease with recent bleeding, patients with spontaneous or acquired impairment of hemostasis ï· Hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see ACTION AND CLINICAL PHARMACOLOGY, Hepatic Impairment) ï· Concomitant treatment with any other anticoagulant, including o unfractionated heparin (UFH), except at doses used to maintain a patent central venous or arterial catheter, o low molecular weight heparins (LMWH), such as enoxaparin and dalteparin, o heparin derivatives, such as fondaparinux, and o oral anticoagulants, such as warfarin, dabigatran, apixaban, rivaroxaban except under circumstances of switching therapy to or from LIXIANA. ï· Pregnancy (See WARNING AND PRECAUTIONS-Special Populations, Pregnant Women) ï· Nursing Women (See WARNING AND PRECAUTIONS-Special Populations, Pregnant Women) ï· Hypersensitivity to edoxaban or to any ingredients of the formulation. For a complete listing of ingredients see DOSAGE FORMS, COMPOSITION AND PACKAGING. WARNINGS AND PRECAUTIONS PREMATURE DISCONTINUATION OF ANY ORAL ANTICOAGULANT, INCLUDING LIXIANA, INCREASES THE RISK OF THROMBOTIC EVENTS. To reduce this risk, consider coverage with another anticoagulant if LIXIANA is discontinued for a reason other than pathological bleeding or completion of a course of therapy (see DOSAGE AND ADMINISTRATION). The following Warnings and Precautions are listed in alphabetical order. Bleeding LIXIANA increases the risk of bleeding and can cause serious, potentially fatal bleeding. Promptly evaluate any signs or symptoms of blood loss. Discontinue LIXIANA in patients with clinically significant active bleeding. LIXIANA, like other anticoagulants, must be used with caution in patients with any increased risk of bleeding. Patients at high risk of bleeding should not be prescribed LIXIANA (see CONTRAINDICATIONS). Should severe bleeding occur, treatment with LIXIANA must be discontinued and the source of bleeding investigated promptly. LIXIANA® (edoxaban) Product Monograph Page 4 of 49